ctDNA and MRD Testing: Emerging Technologies and Clinical Applications
The phenomenon of tumors shedding cell-free DNA into the blood has opened exciting opportunities in cancer diagnosis, monitoring, and treatment. Initial applications have focused on “liquid biopsy”, to identify clinically actionable mutations when tissue is not available. More recently, emerging technologies have enabled the accurate assessment of molecular residual disease (MRD) in solid cancers, to enable patient stratiﬁcation in the adjuvant setting, treatment response monitoring, and recurrence monitoring. These MRD technologies also promise to transform and disrupt clinical research, by enabling new trial designs enriched for MRD-positive patients and new surrogate endpoints based on MRD clearance. In this event, we will explore the various technologies being used for liquid biopsy and MRD assessment, as well as the data and applications with highest potential utility in clinical practice and research.
Sunil Badve, MD | Indiana University
Samuel Klempner, MD | Massachusetts General Hospital
Arturo Loaiza Bonilla, MD | Cancer Treatment Centers of America
Rutika Mehta, MD | Moffitt Cancer Center
Deﬁne ctDNA, cfDNA, MRD, and the clinical evolution and application of these terms in monitoring for recurrence
Understand the different intent between liquid biopsy (therapy selection) versus MRD monitoring
Understand the clinical utility of MRD monitoring in GI, speciﬁcally in various stages of colorectal cancers
Understand various MRD monitoring methodologies: personalized, tumor-informed vs static, tumor naïve
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 CreditsTM for physicians and 1.75 contact hours for nurses and 1.75 of knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
How Does This Course Works
This course is a 1 hour and 45 minute video on ctDNA and MRD Testing: Emerging Technologies and Clinical Applications.
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
A link to the evaluation will be provided at the conclusion of the course.
If you have questions regarding this enduring material activity, please contact us at firstname.lastname@example.org.
Frequently Asked Questions
How do I access my CME/CE Credits?
A link will be provided you to you at the conclusion of the course. You will be asked to fill out a brief evaluation and your certificate will be automatically emailed back to you.
How long do I have access to the course?
Can I have face to face interation with Instructor
How many credits can I obtain?
Amedco LLC designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 CreditsTM for physicians and 1.75 contact hours for nurses and 1.75 of knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.